Precision BioSciences Q1 net loss narrows to $25.1M; cash runway through Q1 2025

PRECISION BIOSCIENCES INC

2023-Q1 EPS reported -$0.23 revenue$8,780,000

Net loss of $25.1M ($0.23/sh) vs $28.2M ($0.46/sh) in Q1 2022; revenue rose to $8.8M from $3.3M on Novartis agreement.
Cash and equivalents $158M; expects runway through Q1 2025.
Azer-cel: 7 patients in expansion cohort; PBCAR19B: 7 at Dose Level 2; updates expected May 2023.
In vivo: PBGENE-HBV targeting CTA/IND in 2024; DMD data at ASGCT; R&D Day mid-2023.
IP: Patent allowed for PCSK9-specific ARCUS nuclease for cardiovascular and gene insertion.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PRECISION BIOSCIENCES INC reported financial results for the first quarter ended March 31, 2023.

Period: the first quarter ended March 31, 2023
Result: reported results

Exact text from the filing

On May 9, 2023, Precision BioSciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2023.

View on SEC.gov

Browse all earnings releases →

PRECISION BIOSCIENCES INC filing history →

Source: SEC EDGAR

accession 0000950170-23-019130

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.